Although a higher proportion of non-GO CBF-AML patients after April 2018 received IDAC vs. HiDAC, there were no significant differences between these two groups with respect to established or potential risk factors such as age, comorbidities, presence of other cytogenetic aberrations or co-mutations (Supplementary Table 1), nor with respect to OS (HR 0.95, 95% CI 0.56–1.61, P = 0.84; Supplementary Fig. 2). This evidence concerns the gene CEBPZ and acute myeloid leukemia.